Join Sagimet Biosciences (#SGMT) for a virtual investor and analyst day on Thurs. May 23 at 1:00pm ET featuring Scott L. Friedman, MD (Icahn School of Medicine at Mount Sinai), who will discuss the unmet need and current treatment landscape for patients with metabolic dysfunction-associated steatohepatitis #MASH. Register here: https://lnkd.in/g46Pa7Jy
Sagimet Biosciences’ Post
More Relevant Posts
-
💙 At Insilico Medicine, our unwavering commitment to supporting those navigating the challenges of rare diseases is at the heart of our mission. Today, on Rare Disease Day, we proudly stand united, celebrating resilience and embracing innovation. 🔬 🔬 Chemistry42, our revolutionary AI-driven software platform, takes a multi-parameter optimization approach to molecule design and discovery, surpassing conventional methods. Did you know it possesses the remarkable ability to generate and design de novo small molecules with precision and purpose? 🌈 And, in a powerful testament to this commitment, our IPF program, designed by Chemistry42, is making waves. The lead drug, the world's first with both a novel AI-discovered target and a novel AI-generated design tailored for Idiopathic Pulmonary Fibrosis, stands as a beacon of hope and progress. Today, we acknowledge not just the challenges but the success stories written by patients through innovative programs like these. Join us in this celebration of resilience and progress, as we collectively raise awareness for Rare Disease Day. Together, we are driving innovation, forging new pathways, and offering hope to those who need it most. 💙🔬 Alex Zhavoronkov Alex Aliper Petrina Kamya, Ph.D. Michelle Chen Jan Szollos, MBA Aisyah Jamil, MD, Msc. Ivan Ozerov Frank Pun Jue Wang Kyle Tretina, PhD Brita Belli Daniil Polykovskiy #DidYouKnow #InnovationInHealthcare #AIinMedicine #InsilicoMedicine #rarediseaseday #Chemistry42 #IPFAwareness #InnovationInHealthcare
-
-
In the journey of drug discovery, selecting the right model is not just a step—it's a leap toward success. Our CEO, Jos Joore, and Director of Biology Discovery, Lenie van den Broek, delve into the limitations of traditional disease models in this video. Watch and learn how MIMETAS' physiologically-relevant 3D disease models can transform your drug discovery process by enabling more accurate clinical predictions. 🔍 Discover how our offerings can accelerate your projects. Watch now and explore our offerings: https://lnkd.in/evue8i28 #DrugDiscovery #ClinicalAccuracy #PredictiveModels
-
📢 Excited to announce the publication of our systematic review titled "Distinct Phenotypical Clusters in #HeartFailure" in Current Heart Failure Reports! This study identifies and summarizes phenotyping studies in heart failure. We analyzed 34 cluster studies (including 19 in HF with preserved ejection fraction) and identified nine overarching phenotypes. Clustering proves robust for discovering clinically distinct phenotypes. However, more effort is now needed to advance future implementation in clinical practice and clinical trial design. Read it here: https://lnkd.in/exyTvKn7 #HeartFailureResearch #OpenAccess #HFphenotypes #ClusterAnalysis Clara Meijs M. Louis Handoko Gianluigi Savarese Robin Vernooij Ilonca Vaartjes Amitava Banerjee Jasper Brugts Folkert Asselbergs
-
-
In the journey of drug discovery, selecting the right model is not just a step—it's a leap toward success. Our CEO, Jos Joore, and Director of Biology Discovery, Lenie van den Broek, delve into the limitations of traditional disease models in this video. Watch and learn how MIMETAS' physiologically-relevant 3D disease models can transform your drug discovery process by enabling more accurate clinical predictions. 🔍 Discover how our offerings can accelerate your projects. Watch now and explore our offerings: https://lnkd.in/evue8i28 #DrugDiscovery #ClinicalAccuracy #PredictiveModels
In the journey of drug discovery, selecting the right model is not just a step—it's a leap toward success. Our CEO, Jos Joore, and Director of Biology Discovery, Lenie van den Broek, delve into the limitations of traditional disease models in this video. Watch and learn how MIMETAS' physiologically-relevant 3D disease models can transform your drug discovery process by enabling more accurate clinical predictions. 🔍 Discover how our offerings can accelerate your projects. Watch now and explore our offerings: https://lnkd.in/evue8i28 #DrugDiscovery #ClinicalAccuracy #PredictiveModels
-
I hope you'll be able to tune into CHI's first webinar of the year (and it's free) next Friday, Jan. 19 with guests Richard Hammerschlag, PhD and Ann Baldwin, PhD. We'll be having an insightful discussion on Biofield Therapies: Guidelines for Reporting Clinical Trials Why Guidelines Are Needed, How They Were Created, What They Can Achieve... Join us by registering here: https://lnkd.in/dEiGYnx . . . . #biofieldscience #biofield #chiwebinars #chihealing #webinarsonhealing
-
-
Learn all about our work in C.elegans and mice with RJx-01 in aging and disease! Our combination drugs helps in the treatment of sarcopenia! Published in JCI Insight https://lnkd.in/ekmRT6cV
We are excited to publish animal model data on our first clinical candidate, RJx-01, showing significant benefits in treating #sarcopenia, the age-related loss of muscle mass and strength, which affects up to 1 in 5 older adults globally. Based on these findings, published in the peer-reviewed #journal JCI Insight, we have started a placebo-controlled Phase 1b #clinicaltrial in 42 elderly volunteers with disuse-induced #muscle #atrophy. Results of this clinical proof-of-mechanism trial are expected later this year. The paper has been published in collaboration with Dr. Caterina Tezze, PharmD, PhD and Dr. Marco Sandri from the Venetian Institute of Molecular Medicine and Padova University in Italy. You can read more about the data in our #publication: https://lnkd.in/gfmviBXW Find out about Rejuvenate in our #pressrelease: https://ow.ly/QAtH50Pvu89
-
-
We are excited to publish animal model data on our first clinical candidate, RJx-01, showing significant benefits in treating #sarcopenia, the age-related loss of muscle mass and strength, which affects up to 1 in 5 older adults globally. Based on these findings, published in the peer-reviewed #journal JCI Insight, we have started a placebo-controlled Phase 1b #clinicaltrial in 42 elderly volunteers with disuse-induced #muscle #atrophy. Results of this clinical proof-of-mechanism trial are expected later this year. The paper has been published in collaboration with Dr. Caterina Tezze, PharmD, PhD and Dr. Marco Sandri from the Venetian Institute of Molecular Medicine and Padova University in Italy. You can read more about the data in our #publication: https://lnkd.in/gfmviBXW Find out about Rejuvenate in our #pressrelease: https://ow.ly/QAtH50Pvu89
-
